key: cord-0726410-re4vgjzf
authors: Kim, Christin
title: The Role of Extracorporeal Membrane Oxygenation in Corona Virus Disease 19 Associated Acute Respiratory Distress Syndrome
date: 2020-10-31
journal: Journal of the National Medical Association
DOI: 10.1016/j.jnma.2020.09.066
sha: 9b7c4ce8202496d4c613cbc309ebc43235e5595d
doc_id: 726410
cord_uid: re4vgjzf

nan

Background: Insomnia involves difficulty falling asleep, maintaining sleep or premature awakening and may increase fatigue and reduce quality of life. Some insomnia treatments impair next day driving performance. Lemborexant is a new dual orexin receptor agonist (DORA) approved for the treatment of insomnia. Objectives: This systematic literature review compared the impact of lemborexant and other insomnia treatments on next day driving performance. Methods: Searches were done in Medline and Embase through May 2019, and in clinical trial registries. Randomized controlled trials (RCTs) included measured performance in a standardized on-road driving test in healthy volunteers or people with insomnia, were published in English, and had ! one group randomized to a recommended dose of benzodiazepines, z-drugs, trazodone, ramelteon or DORAs. Quality of trial was assessed using the National Institute for Health and Care Excellence (NICE) checklist for RCTs. Pairwise random-effects meta-analyses assessed the difference between each active treatment and placebo in standard deviation of lateral position (SDLP). Interpretation of clinical significance was based on the established benchmark equating a difference in SDLP versus placebo of +2.4 cm with a blood alcohol concentration of 0.05%. Results: A total of 14 studies were included. Publication dates ranged from 1984 to 2019. Clinically significant differences in SDLP compared with placebo were shown in healthy volunteers for zopiclone (10/10 studies) and ramelteon (1/1 study), and in people with insomnia for flunitrazepam (2/3 studies). Premature termination of the driving test was reported most frequently for zopiclone (5/10 studies). Lemborexant 5 mg or 10 mg had no statistically or clinically significant difference from placebo in SDLP, and no premature driving test terminations (1/1 study). Conclusion: Zopiclone (z-drug), ramelteon and flunitrazepam (benzodiazepine) were associated with impaired driving performance, similar to driving under the influence of alcohol. Premature test termination was reported most frequently for zopiclone. Lemborexant 5 mg or 10 mg had no significant effect on driving performance and no premature test terminations. Financial support: Eisai Inc. was the funding source and was involved with all stages of the study conduct and analysis. Description: ECMO has becoming accepted as part of the therapeutic algorithm in the treatment of traditional ARDS refractory to conventional medical management, including lung protective ventilation, neuromuscular relaxation and proning. With the spread of the COVID-19 Global Pandemic to Europe and North America the utilization of ECMO in COVID-19 associated ARDS has increased exponentially over the past several months. With a limited body of evidence relating to COVID-19 associated ARDS and the use of ECMO, the role of ECMO in treating this disease remains to be defined. However, in environments where this resource can be provided, ECMO continues to be recommended as a therapeutic option, with data collected thus far suggesting promising outcomes. Given the significant morbidity and mortality related to COVID-19 associated ARDS, many ECMO centers have considered revising criteria for determining which patients to place onto ECMO, excluding patients with advanced age, higher BMI and in multi-system failure. Early engagement of Palliative Care Medicine is recommended to facilitate establishing goals of care for patients placed onto ECMO. Discussion: With its established role in the treatment of traditional ARDS, ECMO has gained increasing acceptance as a treatment modality in COVID-19 associated ARDS refractory to standard medical therapies. As the number of patients receiving ECMO for COVID-19 associated ARDS continues to increase, data not only relating to outcomes, but also to demography would be valuable in identifying disparities to accessing this potentially life-saving treatment modality.

Internal Medicine 50,712

Introduction: The dual orexin receptor antagonist lemborexant (LEM) is approved in the United States and Japan for the treatment of insomnia in adults and the elderly (age !65y). In pivotal study E2006-G000-303 (Study 303; SUNRISE-2; NCT02952820), LEM showed significant benefit compared with placebo (PBO) on sleep onset and maintenance measures over 6 mo in adults age !18y; these benefits continued over 12 mo. This analysis examined efficacy and safety data for LEM across 12 mo from the elderly subgroup of Study 303. consistent with those reported in the first 6 months of treatment for subjects randomized initially to LEM at study baseline. Conclusions: In a 12-month Phase 3 study, LEM efficacy vs PBO was observed by the first week of treatment and sustained across 6 months of LEM treatment. PBO subjects rerandomized to LEM for the second 6 months displayed additional sleep outcome improvements beyond their PBO-related response during the first 6 months. LEM was well tolerated in these subjects. Background: While the role of antiplatelet therapy and statins in preventing thrombosis after stent placement have been established, other factors such as substance use have also been found to be important. For example, several case studies report a higher risk of thrombosis following cocaine use [1] , [2] and one small study showed an increased rate of thrombosis on long term follow up [3] . To our knowledge, there is no US-based national level study that explores substance abuse both in general and broken down to specific substances and its relationship with thrombosis after stenting. Given the possible reluctance of clinicians to proceed with coronary artery stenting for concerns of thrombosis in this particularly high-risk group, it is important to examine and quantify this risk. Our study attempts to bridge this gap by investigating thrombosis after stenting among polysubstance abuse patients relative to the general population. Methods: We used the National Inpatient Sample database (2005-2014) to identify patients who had a history of percutaneous coronary intervention (PCI) and their rate of thrombosis, demographic characteristics, and comorbidities were explored. We then compared the proportion of individuals using various substances grouped by the occurrence of thrombosis, and the rate of thrombosis by substance used. Finally, we performed a logistic regression using stent thrombosis as the primary outcome and substance abuse as the primary exposure while controlling for age, gender, race, medical comorbidities, and the total number of substances used. Results: Of 2,261,263 patients with a history of PCI, 45,132 (2%) had thrombosis after stenting. Most of the patients were male (61%) and white (69%). Only 36537 (1.62%) had a history of substance abuse. 51,641(2.28%) and 12,995(0.57%) had a history of alcohol and cocaine abuse respectively. Multivariate regression with substance abuse as the primary exposure was not statistically significant. However using the individual substances as the primary exposure, we found the odds of stent thrombosis was 2.53 (p<0.01) times higher respectively among cocaine and cannabis users compared to non-users. However, the odds of thrombosis were lower among alcohol and opioid users (0.69 and 0.70 respectively) compared to non-users. Conclusion: Stent thrombosis is increased among cocaine and cannabis users but we found no increased risk among alcohol and opioid users. continued.

Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study

Peripheral Arterial Disease Fact SheetjData & StatisticsjDHDSPjCDC

Reducing amputation rates in critical limb ischemia patients via a limb salvage program: A retrospective analysis

Critical limb ischemia: current challenges and future prospects

Approach to the patient with peripheral arterial disease

Insomnia treatments and on-the-road driving performance: a systematic literature review